Sclerotherapy for HHT Nosebleeds — Made Simpler
A new international expert consensus published in August 2025 confirms that sclerotherapy is a safe, effective, and patient-friendly treatment for HHT-related nosebleeds.
Evidence-based
Six international HHT experts agreed on clear guidelines following a formal Delphi consensus.
Patient-friendly
Often delivered as an outpatient procedure, frequently without general anaesthesia, with high patient satisfaction.
Proven outcomes
Studies show reduced nosebleed severity and improved quality of life.
What the Consensus Says
- Stable HHT patients may be treated with sclerotherapy, with individual clinical assessment
- Treatment can be safely performed in outpatient settings
- Side effects are usually mild to moderate; serious complications are rare
- Specific safety measures are recommended to minimise risk
What the Research Shows
-
A 2023 systematic review of seven studies (196 patients) showed clear improvement in nosebleed severity
-
A Madrid intervention study reported a significant reduction in Epistaxis Severity Score and improved quality of life after treatment
-
Additional case series describe effective treatment without scarring
From patient idea to international consensus
This consensus was initiated by the HHT Italy patient organisation and supported by HHT Spain, AMRO France, Cure HHT, and international experts. It highlights how patient-led initiatives can directly shape high-quality scientific research.
Why does this matter in Ireland?
For many years, sclerotherapy in Ireland was met with caution due to limited published evidence. That gap has now been filled. International consensus and multiple studies provide a strong foundation for informed discussion and access to care.
A note from HHT Ireland
HHT Ireland does not advocate for any specific treatment. Our role is to ensure that patients and clinicians are aware of all internationally recognised, research-supported treatment options.
Treatment decisions should always be made by patients in consultation with their medical teams.